Tiziana Life Sciences
- Country
- ๐ฌ๐งUnited Kingdom
- Ownership
- -
- Employees
- 9
- Market Cap
- $125.8M
- Introduction
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 30
- Registration Number
- NCT01301391
- Locations
- ๐บ๐ธ
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
๐บ๐ธNIH, Center for Cancer Research, Medical Oncology, Bethesda, Maryland, United States
๐ฎ๐นFondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, (mi), Italy
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Tiziana Life Sciences LTD
- Target Recruit Count
- 72
- Registration Number
- NCT01011439
- Locations
- ๐บ๐ธ
TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
๐บ๐ธNIH, Center for Cancer Research, Medical Oncology, Bethesda, Maryland, United States
๐ซ๐ทHopital Larrey, Toulouse Cedex, France